Stock AnalizXencor Inc XNCR
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Xencor Inc (XNCR) is a healthcare company listed in the US with a market value of about $2.8B. In the twelve months to September 30, 2026 it had revenue of $200M and net income of -$118M, a net margin of -58.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 0% a year, a 5-year average ROIC of -9%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $200M | $126M | $110M | $175M | $165M | $275M | $123M | $157M | $41M | $46M | $109M |
| Net income | -$118M | -$92M | -$233M | -$133M | -$55M | $83M | -$69M | $27M | -$70M | -$38M | $45M |
| Free cash flow | -$176M | -$138M | -$208M | -$96M | -$14M | -$30M | -$16M | $57M | -$87M | -$39M | $94M |
| EPS (diluted) | $-1.59 | $-1.24 | $-3.58 | $-2.20 | $-0.93 | $1.37 | $-1.21 | $0.46 | $-1.31 | $-0.82 | $1.07 |
| Net margin | -58.8% | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -83.4% | 41.4% |
| ROIC | — | -17.0% | -15.5% | -11.4% | -8.3% | 5.7% | -13.2% | 2.3% | -15.2% | -13.5% | 12.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $42.50, 15% above the current price; targets range from $21.00 to $70.00; the consensus rating is “Strong buy”; expected EPS is $-2.27 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Xencor pay a dividend?
Not currently.
Is Xencor a good stock to buy?
We do not give buy or sell advice. Xencor scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.